Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'

A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices.

What Happened: The clash, unfolding as of Friday, has reignited discussions on Pharmacy Benefit Managers (PBMs) and Big Pharma's tax practices, with the Senate poised to address reform amid rising public scrutiny.

Enter Cuban, the Dallas Mavericks owner and founder of Cost Plus Drugs, who fired back with a pointed correction.

Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — you can become an investor for $0.80 per share today.

In a post quoting Warren, Cuban argued that PBMs—not Big Pharma—are the true culprits behind inflated drug prices.

“PBMs corrupt healthcare,” he wrote, explaining that these intermediaries control formularies and manipulate prices to maximize rebate revenue, with three major PBMs negotiating over 90% of rebates for commercial insurance plans.

Warren, in her post, had blamed pharmaceutical giants like Johnson & Johnson JNJ and Pfizer Inc. PFE for charging Americans the “highest drug prices in the world” while paying “zero dollars in federal taxes.”

Citing data from her Senate Finance Committee role, Warren highlighted how these companies, alongside AbbVie Inc. ABBV, Amgen Inc. AMGN, and Merck & Co Inc. MRK, have exploited tax loopholes from the 2017 Tax Cuts and Jobs Act to shield billions in profits.

“Republicans want to make it worse. I’m fighting back,” she declared, sharing a CNBC headline and urging action against what she calls a “rigged tax system.”

See Also: Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can invest with $1,000 at just $0.30/share.

Why It Matters: Cuban has been a critic of the healthcare system, saying that it should be simple. According to him, it’s become overly complicated by big insurance companies and PBMs.

These groups, he says, act as middlemen, controlling not just the costs but also the accessibility of care.

He blames PBMs for lack of transparency, inflated specialty drug prices, rebate distortion, formulary restrictions, and “Sh–ing on” on independent pharmacies.

Some significant firms engaged in the PBM business listed in the U.S. include;

Meanwhile, here is how some pharmaceutical sector ETFs have performed;

The SPDR S&P 500 ETF Trust SPY and Invesco QQQ Trust ETF QQQ, which track the S&P 500 index and Nasdaq 100 index, respectively, were mixed in premarket on Friday. The SPY was down 0.30% at $595.67, while the QQQ was 0.015% higher at $529.07, according to Benzinga Pro data.

Read Next:

• Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential.
• If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it?

Photo courtesy: Shutterstock